Meta-analysis of the effects of ABCB1 genotype on the efficacy and safety of taxanes in the treatment of breast cancer
- VernacularTitle:ABCB1基因型对紫杉烷类药物用于乳腺癌疗效和安全性影响的Meta分析
- Author:
Shufang ZHANG
1
;
Yan LI
2
;
Lun LIU
1
;
Xiaoning GENG
1
;
Bo ZHOU
3
;
Zhongtao ZHANG
4
;
Fulei LIU
5
Author Information
1. Dept. of Pharmacy，the Affiliated Taian City Central Hospital of Qingdao University，Shandong Taian 271099，China
2. Dept. of Clinical Pharmacy，the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital），Jinan 250014，China
3. Dept. of Postdoctoral Workstation，the Affiliated Taian City Central Hospital of Qingdao University，Shandong Taian 271099，China
4. Laboratory of Precision Intervention and Translational Medicine in Oncology，the Affiliated Taian City Central Hospital of Qingdao University，Shandong Taian 271099，China
5. Dept. of Scientific Research，the Affiliated Taian City Central Hospital of Qingdao University，Shangdong Taian 271099，China
- Publication Type:Journal Article
- Keywords:
breast cancer;
ABCB1 genotypes;
gene polymorphism;
paclitaxel;
docetaxel;
efficacy;
safety
- From:
China Pharmacy
2024;35(10):1254-1259
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effects of ABCB1 genotypes on the efficacy and safety of taxanes in the treatment of breast cancer. METHODS By searching Embase，the Cochrane Library， PubMed， CNKI， and Wanfang databases， cohort studies and case-control studies about taxanes in the treatment of breast cancer were collected from the establishment of the database to July 2023. After screeningliterature， extracting data and evaluating quality， meta-analysis was performed by using RevMan 5.3 software. RESULTS A total of 11 studies were included， involving 1 321 patients. There was no correlation between the three genotypes and effective rate， the incidence of myelosuppression， the incidence of neurotoxicity （except for the allele and recessive model of ABCB1 C1236T）， and the incidence of hypersensitivity reactions （P＞0.05）. The subgroup analysis showed that there was a correlation between ABCB1 C1236T dominant model and effective rate when using anthracyclines+5-fluorouracil+cyclophosphamide+taxanes （P＜0.05）， there was a correlation between ABCB1 C3435T recessive model and effective rate when using taxanes+trastuzumab （P＜0.05）. ABCB1 C1236T allele model and recessive model were correlated with sample size ≥100 and using cyclophosphamide+epirubicin+5- fluorouracil+paclitaxel or cyclophosphamide+epirubicin+paclitaxel+trastuzumab or cyclophosphamide+epirubicin+5-fluorouracil+ trastuzumab+paclitaxel regimens； recessive model with sample size ＜100 and the African region were correlated with the incidence of peripheral neuropathy； recessive model was correlated with cutaneous adverse reactions （P＜0.05）. ABCB1 C3435T recessive model was correlated with the incidence of reduced neutrophil count with sample size ≥100； the incidence of white blood cell count reduction with sample size ＜100 and using docetaxel+epirubicin+cyclophosphamide was correlated with both the allele model and the dominant model； the incidence of infections was correlated with the dominant model （P＜0.05）. The incidence of neutrophil count reduction with the sample size ＜100 was correlated with allele model of ABCB1 G2677T/A； the incidence of edema with sample size ≥100 was correlated with allele model and recessive model； the incidence of infection was correlated with allele model and dominant model， especially in patients with neutrophil count complicated with fever （P＜0.05）. CONCLUSIONS ABCB1 genotypes are not correlated with effective rate of taxanes in the treatment of breast cancer， but ABCB1 C3435T genotype is associated with decreased neutrophil counts， decreased white blood cell counts and infections； ABCB1 C1236T genotype is associated with neurotoxicity and cutaneous adverse reactions； ABCB1 G2677T/A genotype is associated with decreased neutrophil counts， infections， and edema.
